We’ve recently updated our valuation analysis.

Diebold Nixdorf Valuation

Is DBD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DBD?

Other financial metrics that can be useful for relative valuation.

DBD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA12.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does DBD's PS Ratio compare to its peers?

The above table shows the PS ratio for DBD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.9x
CRSS Crossroads Impact
0.2xn/aUS$160.3m
QMCO Quantum
0.3x5.6%US$131.9m
IMMR Immersion
6.5x-10.9%US$255.6m
HEAR Turtle Beach
0.7x14.6%US$165.9m
DBD Diebold Nixdorf
0.05x5.2%US$164.5m

Price-To-Sales vs Peers: DBD is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (1.9x).


Price to Earnings Ratio vs Industry

How does DBD's PE Ratio compare vs other companies in the US Tech Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a3.7%
n/an/an/a

Price-To-Sales vs Industry: DBD is good value based on its Price-To-Sales Ratio (0x) compared to the US Tech industry average (0.9x)


Price to Sales Ratio vs Fair Ratio

What is DBD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DBD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.05x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: DBD is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Share Price vs Fair Value

What is the Fair Price of DBD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DBD ($2.08) is trading below our estimate of fair value ($42.69)

Significantly Below Fair Value: DBD is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DBD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.08
US$4.00
+92.3%
25.0%US$5.00US$3.00n/a2
Nov ’23US$2.44
US$4.00
+63.9%
25.0%US$5.00US$3.00n/a2
Oct ’23US$2.44
US$5.00
+104.9%
0%US$5.00US$5.00n/a2
Sep ’23US$3.62
US$5.67
+56.5%
16.6%US$7.00US$5.00n/a3
Aug ’23US$3.32
US$5.67
+70.7%
16.6%US$7.00US$5.00n/a3
Jul ’23US$2.31
US$5.67
+145.3%
16.6%US$7.00US$5.00n/a3
Jun ’23US$2.94
US$5.67
+92.7%
16.6%US$7.00US$5.00n/a3
May ’23US$4.10
US$9.75
+137.8%
16.8%US$11.00US$7.00n/a4
Apr ’23US$6.61
US$11.75
+77.8%
16.3%US$15.00US$10.00n/a4
Mar ’23US$7.81
US$11.75
+50.4%
16.3%US$15.00US$10.00n/a4
Feb ’23US$9.54
US$15.00
+57.2%
33.0%US$23.00US$10.00n/a4
Jan ’23US$9.05
US$15.00
+65.7%
33.0%US$23.00US$10.00n/a4
Dec ’22US$7.96
US$15.00
+88.4%
33.0%US$23.00US$10.00US$2.094
Nov ’22US$9.28
US$15.00
+61.6%
33.0%US$23.00US$10.00US$2.444
Oct ’22US$10.36
US$17.25
+66.5%
21.8%US$23.00US$13.00US$2.444
Sep ’22US$10.94
US$17.25
+57.7%
21.8%US$23.00US$13.00US$3.624
Aug ’22US$10.41
US$17.25
+65.7%
21.8%US$23.00US$13.00US$3.324
Jul ’22US$12.71
US$19.25
+51.5%
17.0%US$23.00US$14.00US$2.314
Jun ’22US$13.80
US$21.00
+52.2%
6.7%US$23.00US$20.00US$2.943
May ’22US$15.01
US$20.33
+35.5%
10.1%US$23.00US$18.00US$4.103
Apr ’22US$14.19
US$20.33
+43.3%
10.1%US$23.00US$18.00US$6.613
Mar ’22US$15.26
US$18.67
+22.3%
5.1%US$20.00US$18.00US$7.813
Feb ’22US$14.60
US$16.33
+11.9%
7.6%US$18.00US$15.00US$9.543
Jan ’22US$10.66
US$12.50
+17.3%
20.0%US$15.00US$10.00US$9.052
Dec ’21US$10.42
US$12.50
+20.0%
20.0%US$15.00US$10.00US$7.962

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies